141 related articles for article (PubMed ID: 9443936)
1. Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications.
Schumacher C; Cioffi CL; Sharif H; Haston W; Monia BP; Wennogle L
Mol Pharmacol; 1998 Jan; 53(1):97-104. PubMed ID: 9443936
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
5. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase.
Monia BP
Ciba Found Symp; 1997; 209():107-19; discussion 119-23. PubMed ID: 9383572
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation.
Cioffi CL; Garay M; Johnston JF; McGraw K; Boggs RT; Hreniuk D; Monia BP
Mol Pharmacol; 1997 Mar; 51(3):383-9. PubMed ID: 9058592
[TBL] [Abstract][Full Text] [Related]
7. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of antisense oligodeoxynucleotides.
Schumacher C
Methods Enzymol; 2000; 314():440-54. PubMed ID: 10565031
[No Abstract] [Full Text] [Related]
9. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
Monia BP; Johnston JF; Geiger T; Muller M; Fabbro D
Nat Med; 1996 Jun; 2(6):668-75. PubMed ID: 8640558
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
11. Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides.
Mandiyan S; Schumacher C; Cioffi C; Sharif H; Yuryev A; Lappe R; Monia B; Hanson S; Goff S; Wennogle L
Antisense Nucleic Acid Drug Dev; 1997 Dec; 7(6):539-48. PubMed ID: 9450911
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.
Phillips JA; Craig SJ; Bayley D; Christian RA; Geary R; Nicklin PL
Biochem Pharmacol; 1997 Sep; 54(6):657-68. PubMed ID: 9310342
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
14. Sequence-specific antiproliferative effects of antisense and end-capping-modified antisense oligodeoxynucleotides targeted against the 5'-terminus of basic-fibroblast-growth-factor mRNA in coronary smooth muscle cells.
Schmidt A; Sindermann J; Peyman A; Uhlmann E; Will DW; Müller JG; Breithardt G; Buddecke E
Eur J Biochem; 1997 Sep; 248(2):543-9. PubMed ID: 9346314
[TBL] [Abstract][Full Text] [Related]
15. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.
Mullen P; McPhillips F; Monia BP; Smyth JF; Langdon SP
Int J Cancer; 2006 Mar; 118(6):1565-71. PubMed ID: 16184551
[TBL] [Abstract][Full Text] [Related]
16. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo.
Monia BP; Sasmor H; Johnston JF; Freier SM; Lesnik EA; Muller M; Geiger T; Altmann KH; Moser H; Fabbro D
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15481-4. PubMed ID: 8986837
[TBL] [Abstract][Full Text] [Related]
17. Co-administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): a role for the scavenger receptor in its in vivo disposition.
Steward A; Christian RA; Hamilton KO; Nicklin PL
Biochem Pharmacol; 1998 Aug; 56(4):509-16. PubMed ID: 9763228
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
19. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty.
Gunn J; Holt CM; Francis SE; Shepherd L; Grohmann M; Newman CM; Crossman DC; Cumberland DC
Circ Res; 1997 Apr; 80(4):520-31. PubMed ID: 9118483
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer.
Mullen P; McPhillips F; MacLeod K; Monia B; Smyth JF; Langdon SP
Clin Cancer Res; 2004 Mar; 10(6):2100-8. PubMed ID: 15041731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
